Skip to main content
SpringerLink
Log in

A sensor augmented pump may improve awareness of hypoglycemia and quality of life in Japanese patients with type 1 diabetes mellitus

  • Original Article
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

Objective

Sensor-augmented pump (SAP) therapy reportedly improves glycemic control and quality of life. However, there is limited information on changes in awareness of hypoglycemia and quality of life (QOL) after starting SAP therapy in Japanese patients with type 1 diabetes. The aim of this study was to evaluate glycemic control, awareness of hypoglycemia, and QOL after initiation of SAP therapy in these patients.

Methods

The study included 20 patients with type 1 diabetes who started SAP therapy. HbA1c levels, values derived from continuous glucose monitoring [including percentages of time in target range (70–180 mg/dL), time below range (< 70 mg/dL), and time above range (> 180 mg/dL)], the Diabetes Treatment Satisfaction Questionnaire score, and the Clarke score were compared between baseline and after 3 and 6 months of SAP therapy.

Results

There was a significant decrease in HbA1c at 3 and 6 months after starting on the SAP (p < 0.0001). There was also a significant decrease in time above range (> 180 mg/dL) at the two time points (p = 0.0069 and p = 0.0042, respectively). There was no significant change in time below range (< 70 mg/dL). There was a significant reduction in the Clarke score (p = 0.0347 and p = 0.0003, respectively) and a significant increase in the treatment satisfaction score (both p < 0.0001). There was no significant change in any of the three MOS 36-Item Short-Form Health Survey v2 component summary scores.

Conclusion

SAP therapy was associated with improvement of glycemic control, mainly by reducing hyperglycemia, and patients’ satisfaction with treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–20.

    Article  CAS  Google Scholar 

  2. Battelino T, Conget I, Olsen B, Schütz-Fuhrmann I, Hommel E, Hoogma R, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012;55:3155–62.

    Article  CAS  Google Scholar 

  3. Matsuoka A, Hirota Y, Urai S, Hamaguchi T, Takeuchi T, Miura H, et al. Effect of switching from conventional continuous subcutaneous insulin infusion to sensor augmented pump therapy on glycemic profile in Japanese patients with type 1 diabetes. Diabetol Int. 2018;9:201–7.

    Article  Google Scholar 

  4. Šoupal J, Petruželková L, Flekač M, Pelcl T, Matoulek M, Daňková M, et al. Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR Study. Diabetes Technol Ther. 2016;18:532–8.

    Article  Google Scholar 

  5. Riemsma R, Corro Ramos I, Birnie R, Büyükkaramikli N, Armstrong N, Ryder S, et al. Integrated sensor-augmented pump therapy systems [the MiniMed® ParadigmTM Veo system and the VibeTM and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. Health Technol Assess. 2016;20:1–251.

    Article  Google Scholar 

  6. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40:1631–40.

    Article  Google Scholar 

  7. Rickels MR, Peleckis AJ, Dalton-Bakes C, Naji JR, Ran NA, Nguyen HL, et al. Continuous glucose monitoring for hypoglycemia avoidance and glucose counterregulation in long-standing type 1 diabetes. J Clin Endocrinol Metab. 2018;103:105–14.

    Article  Google Scholar 

  8. Tanaka S, Ohmori M, Awata T, Shimada A, Murao S, Maruyama T, et al. Diagnostic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) (2012): report by the committee on slowly progressive insulin-dependent (type 1) diabetes mellitus of the Japan Diabetes Society. Diabetol Int. 2015;6:1–7.

    Article  Google Scholar 

  9. Imagawa A, Hanafusa T, Awata T, Ikegami H, Uchigata Y, Osawa H, et al. Report of the committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). Diabetol Int. 2012;3:179–83.

    Article  Google Scholar 

  10. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19:644–55.

    Article  CAS  Google Scholar 

  11. Schlichtkrull J, Munck O, Jersild M. The M-value, an index of blood-sugar control in diabetics. Acta Med Scand. 1965;177:95–102.

    Article  CAS  Google Scholar 

  12. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care. 2019;42:1593–603.

    Article  Google Scholar 

  13. Bradley C (1994) Diabetes treatment satisfaction questionnaire: (DTSQ). In: Handbook of Psychology and Diabetes. Routledge, 111–132.

  14. Ishii H, Bradley C, Riazi A, Barendse S, Yamamoto T. The Japanese version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ): translation and clinical evaluation [in Japanese]. Igaku no Ayumi. 2000;192:809–14.

    Google Scholar 

  15. Fukuhara S, Suzukamo Y. Manual of SF-36v2 Japanese version [in Japanese]. Kyoto: iHope International Inc. 2014, 2019.

  16. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM: A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care. 1995;18:517–22.

    Article  CAS  Google Scholar 

  17. Yokota T, Utsunomiya K. The investigation on impaired awareness of hypoglycemia (IAH) in Japan [in Japanese]. J Japan Diab Soc. 2015;58:446–52.

    Google Scholar 

  18. Namba M, Iwakura T, Nishimura R, Akazawa K, Matsushita M, Atsumi Y, et al. The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: a report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society. Diabetol Int. 2018;9:84–99.

    Article  Google Scholar 

  19. Diabetic Retinopathy Study Research Group (1981) Report number 7. A modification of the Airlie House Classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy Study Group. Investig Opthalmology Vis Sci 21:210–26.

  20. Haneda M, Utsunomiya K, Koya D, Babazono T, Moriya T, Makino H, et al. A new classification of diabetic nephropathy 2014: a report from joint committee on Diabetic Nephropathy. Diabetol Int. 2014;5:207–11.

    Article  Google Scholar 

  21. Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H, et al. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Diabetes Care. 2009;32:2245–50.

    Article  CAS  Google Scholar 

  22. Takita M, Miura J, Hoshina S, Tsuchida Y, Kobayashi H, Uchigata Y, et al. Glycemic control and variability after initiation of SAP compared by treatment before initiation—effect of SAP compared by treatment before pre-treatment – [in Japanese]. J Japan Innov Diabetes Treat. 2017;13:15–22.

    Google Scholar 

  23. van Beers CAJ, DeVries JH, Kleijer SJ, Smits MM, Geelhoed-Duijvestijn PH, Kramer MHH, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016;4:893–902.

    Article  Google Scholar 

  24. Heinemann L, Freckmann G, Ehrmann D, Faber-Heinemann G, Guerra S, Waldenmaier D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018;391:1367–77.

    Article  CAS  Google Scholar 

  25. Ly TT, Gallego PH, Davis EA, Jones TW. Impaired Awareness of Hypoglycemia in a Population-Based Sample of Children and Adolescents With Type 1 Diabetes. Diabetes Care. 2009;32:1802–6.

    Article  Google Scholar 

  26. Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med. 2008;25:501–4.

    Article  CAS  Google Scholar 

  27. Geddes J, Wright RJ, Zammitt NN, Deary IJ, Frier BM. An Evaluation of Methods of Assessing Impaired Awareness of Hypoglycemia in Type 1 Diabetes. Diabetes Care. 2007;30:1868–70.

    Article  CAS  Google Scholar 

  28. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self-monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ. 2011;343:d3805–d3805.

    Article  Google Scholar 

  29. Lin YK, Fisher SJ, Pop-Busui R. Hypoglycemia unawareness and autonomic dysfunction in diabetes: Lessons learned and roles of diabetes technologies. J Diabetes Investig. 2020;11:1388–402.

    Article  Google Scholar 

  30. Little SA, Leelarathna L, Walkinshaw E, Tan HK, Chapple O, Lubina-Solomon A, et al. Recovery of Hypoglycemia Awareness in Long-standing Type 1 Diabetes: A Multicenter 2 × 2 Factorial Randomized Controlled Trial Comparing Insulin Pump With Multiple Daily Injections and Continuous With Conventional Glucose Self-monitoring (HypoCOMPaSS). Diabetes Care. 2014;37:2114–22.

    Article  CAS  Google Scholar 

  31. Hermanides J, Nørgaard K, Bruttomesso D, Mathieu C, Frid A, Dayan CM, et al. Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabet Med. 2011;28:1158–67.

    Article  CAS  Google Scholar 

  32. Rubin RR, Peyrot M. Health-related quality of life and treatment satisfaction in the sensor-augmented pump therapy for A1C reduction 3 (STAR 3) trial. Diabetes Technol Ther. 2012;14:143–51.

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank Dr. Takashi Murata (Diabetes Center, National Hospital Organization Kyoto Medical Center, Kyoto, Japan) for constructive discussions and critical reading of the manuscript.

Author information

Authors and Affiliations

  1. Diabetes Center, Tokyo Women’s Medical University School of Medicine, 8-1 Kawada-cho Shinjuku, Tokyo, 162-8666, Japan

    Satoshi Takagi, Junnosuke Miura, Kanako Shimura, Sari Hoshina, Mikako Takita, Shota Mochizuki, Zhuo Shen, Takuya Asanuma, Hiroko Takaike & Tetsuya Babazono

  2. Department of Nursing, Tokyo Women’s Medical University Hospital, 8-1 Kawada-cho Shinjuku, Tokyo, 162-8666, Japan

    Yukiko Tsuchida

Authors
  1. Satoshi Takagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Junnosuke Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kanako Shimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sari Hoshina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yukiko Tsuchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mikako Takita
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shota Mochizuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhuo Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takuya Asanuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hiroko Takaike
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tetsuya Babazono
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Junnosuke Miura.

Ethics declarations

Conflict of interest

TB is supported through unrestricted research funding: Novartis Pharma KK, Eli Lilly Japan K.K., Honoraria (e. g. lecture fees): Novo Nordisk Pharma Ltd., MSD K.K., Takeda Pharmaceutical Company Limited, Taisho Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., and Subsidies or Donations: Terumo Corporation, TEIJIN PHARMA LIMITED, Abbott Japan LLC, Sumitomo Dainippon Pharma Co., Ltd., Ono Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Baxter Limited, Alcon Japan Ltd., Chugai Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., NIPRO CORPORATION, MSD K.K., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Co., Ltd., Taisho Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd, Santen Pharmaceutical Co., Ltd., SANWA KAGAKU KENKYUSHO CO., LTD.. ST, JM, KS, SH, YT, MT, SM, ZS, TA, and HK declare that they have no conflict of interest.

Human rights statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (the ethics committee of Tokyo Women’s Medical University; approval number 181203; date of approval, December 7, 2018) and with the Helsinki Declaration of 1964 and later versions. Written informed consent were obtained from all subjects prior to enrollment in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takagi, S., Miura, J., Shimura, K. et al. A sensor augmented pump may improve awareness of hypoglycemia and quality of life in Japanese patients with type 1 diabetes mellitus. Diabetol Int 13, 280–287 (2022). https://doi.org/10.1007/s13340-021-00538-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-021-00538-x

Keywords

Search

Navigation